Drug Profile
Bromocriptine
Alternative Names: Bromocriptine mesylate; Bromocriptine-QR; CB 154; Cycloset; Ergoset; PLD 165Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator VeroScience LLC
- Developer Salix Pharmaceuticals; VeroScience
- Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Ergolines; Ergotamines; Infertility therapies; Small molecules
- Mechanism of Action Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Type 2 diabetes mellitus
- Discontinued Atherosclerosis; Breast cancer; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In adolescents, In children) in USA (PO, Immediate release)
- 01 Jun 2016 VeroScience completes a phase-I clinical trial in Type-2 diabetes mellitus (in children and adolescents) in USA (PO)
- 15 Jun 2015 Adverse events data from a phase III trial in Type 2 diabetes mellitus released by VeroScience